Sign in

CIK 0001817713

  • Large accelerated filer

Janux Therapeutics, Inc.

Sign in to watch
Ticker
JANX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
822289112
Phone
+1 858-751-4493
Business address
10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO, CA, 92130
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 38 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-06-03 Avalon Ventures XI, L.P. 10% owner Sale −691,525 $54.75 $37.9M 3,340,018
2024-03-04 RA CAPITAL MANAGEMENT, L.P. Director Purchase · Pre-Funded Warrants (Right to Buy) +1,397,849 $46.50 $65.0M 1,397,849
2024-02-29 Avalon Ventures XI, L.P. 10% owner Other disposition −438,722 3,948,495
2024-02-29 Avalon Ventures XI, L.P. 10% owner Other acquisition +11,388 11,388
2024-02-29 Avalon Ventures XI, L.P. 10% owner Other disposition −11,388 0
2024-02-29 Avalon Ventures XI, L.P. 10% owner Other disposition −447,949 4,031,543
2024-02-29 Avalon Ventures XI, L.P. 10% owner Other acquisition +31,456 31,456
2024-02-29 Avalon Ventures XI, L.P. 10% owner Other disposition −31,456 0
2024-02-29 Avalon Ventures XI, L.P. 10% owner Other disposition −84,985 764,869
2024-02-29 Avalon Ventures XI, L.P. 10% owner Other acquisition +1,700 1,700
2024-02-29 Avalon Ventures XI, L.P. 10% owner Other disposition −1,700 0
2024-02-29 Gujrathi Sheila Director Other acquisition +2,986 108,028
2024-02-29 CAPPS VICKIE L Director Other acquisition +1,493 65,543
2024-01-02 Winter Charles M. Chief Technical Officer Grant or award · Stock Option (right to buy) +111,000 111,000
2024-01-02 Robinson Byron Chief Strategy Officer Grant or award · Stock Option (right to buy) +151,500 151,500
2024-01-02 Reardon Tighe Acting Chief Financial Officer Grant or award · Stock Option (right to buy) +157,000 157,000
2024-01-02 Meyer Andrew Hollman Chief Business Officer Grant or award · Stock Option (right to buy) +105,000 105,000
2024-01-02 Campbell David Alan President and CEO Grant or award · Stock Option (right to buy) +356,500 356,500
2024-01-02 DiRaimondo Thomas Chief Scientific Officer Grant or award · Stock Option (right to buy) +147,000 147,000
2023-11-13 Reardon Tighe Acting Chief Financial Officer Purchase +849,854 $5.87 $5.0M 849,854

Page 14 of 15 · 294 trades